Bridgehead International Appoints Expert in Global Pricing and Market Access for Oncology Products

Melton Mowbray 17 October 2011 ......Bridgehead International is pleased to announce the appointment of Chris Teale as Principal Consultant.

Chris joins Bridgehead from AstraZeneca, where he was Director of Global Pricing and Market Access (Oncology) and brings with him extensive practical and academic experience within the pharmaceutical industry, across both Marketing and R&D.  He has held a number of leadership positions at both a Global and European level, having previously been Director Health Economics, Pricing and Reimbursement and Access at Allergan and Portfolio Planning Manager at Ciba-Geigy in Switzerland.

In his market access roles, Chris has developed global pricing strategies for a wide range of products and therapy areas including personalised healthcare products and orphan drugs.  He led the “Innovate for Access” programme at AstraZeneca which identified creative and innovative approaches to overcoming market access hurdles.

Chris has a BSc in Mathematics from Newcastle University, and has studied at Loughborough University (Management Information Systems) and INSEAD Business School (Marketing for International Business).  He is also an occasional lecturer on health economics / pricing and reimbursement on the TOPRA / University of Wales MSc course.

Bridgehead International CEO, Timothy Fitzgerald commented; “Pricing, reimbursement and market access represents perhaps the greatest area of challenge for the pharmaceutical, device and diagnostics sectors”. “Chris’s experience and expertise will be invaluable to our clients as they seek to develop strategies which are up to the challenge”.

Notes to editors:

About Bridgehead International Ltd

Bridgehead is a leading strategic healthcare consultancy group, providing a range of services designed to assist clients in achieving extraordinary growth across the product and technology value chain.

Bridgehead's mission is to work with commercial organisations, government agencies and the investment community to ensure that:

• Companies have the funding, structure and strategic focus to deliver high levels of innovation and financial return
• Patients have rapid and broad access to new innovative medicines, medical devices and diagnostic tools, particularly in areas of high unmet need.

With over 50 consultants and 60 associates in Europe, North America and Asia, Bridgehead provides a powerful combination of strategic, scientific, medical, technical, commercial, economic, decision support, modelling and intellectual property skills and experience. 

Bridgehead is globally recognised for its expertise in:

• Market access strategy
• Pricing and reimbursement strategy
• Health economics and health technology assessment
• Opportunity evaluation
• Transaction support.

In 2007 and 2011, Bridgehead was honoured with The Queen’s Award for Enterprise, for outstanding achievement in international trade. The Queen’s Award for Enterprise is the highest honour that can be bestowed upon a UK company and is the UK’s top award for business performance.

In 2009, Bridgehead was voted UK Strategic Advisor of the Year – Healthcare, in the ACQ Finance Magazine’s Global Awards.

For more information about Bridgehead International, please see http://www.bridgehead.com

Contacts at Bridgehead International:

Oct 17, 2011